Schoninger SF, Blain SW. The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer. Mol Cancer Ther. 2020;19(1):3–12.
Preusser M, De Mattos-Arruda L, Thill M, et al. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion [published correction appears in ESMO Open. 2019 Mar 11;4(2):e000368corr1]. ESMO Open. 2018;3(5):e000368.
Niu Y, Xu J, Sun T. Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies. J Cancer. 2019;10(22):5504–5517. Published 2019 Aug 29. doi:10.7150/jca.32628
Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001;411, 1017–1021.
Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019; 381:307-316.
Li M, Xiao A, Floyd D, et al. CDK4/6 inhibition is more active against the glioblastoma proneural subtype. Oncotarget. 2017;8(33):55319–55331.
van Caloen G, Machiels JP. Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck. Curr Opin Oncol. 2019;31(3):122–130.
Zhang YX, Sicinska E, Czaplinski JT, et al. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther. 2014;13(9):2184–2193.
Chaturvedi NK, Hatch ND, Sutton GL, et al. A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib. Leuk Lymphoma. 2019;60(5):1214–1223.
Kollmann K, Briand C, Bellutti F, et al. The interplay of CDK4 and CDK6 in melanoma. Oncotarget. 2019;10(14):1346–1359.
Goldstein AM, Chidambaram A, Halpern A, et al. Rarity of CDK4 germline mutations in familial melanoma. Melanoma Res. 2002;12(1):51–55.
Rihani A, Vandesompele J, Speleman F, et al. Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma. Cancer Cell Int. 2015;15:76.
Geoerger B, Bourdeaut F, DuBois SG, et al. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clin Cancer Res. 2017;23(10):2433–2441.
Pacheco J, Schenk E. CDK4/6 inhibition alone and in combination for non-small cell lung cancer. Oncotarget. 2019;10(6):618–619.
Franco J, Witkiewicz AK, Knudsen ES. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget. 2014;5(15):6512–6525.
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
